Targeted Oncology Staff

During a Targeted Oncology™ Case-Based Roundtable™ event, Alicia K. Morgans, MD, MPH, and participants discussed situations when they would use a PARP inhibitor to treat patients with metastatic castration-resistant prostate cancer in the second or third line. This is the first of 2 articles based on this event.

During a Targeted Oncology™ Case-Based Roundtable™ event, Rami Komrokji, MD, discussed the use of JAK inhibitors for treatment of patients with primary myelofibrosis.

During a Targeted Oncology™ Case-Based Roundtable™ event, Sumit Madan, MD, and participants discussed the therapies listed on the National Comprehensive Cancer Network guidelines for patients with relapse after 1 or more prior lines of therapy. This is the first of 2 articles based on this event.

During a Targeted Oncology™ Case-Based Roundtable™ event, Edward S. Kim, MD, MBA, and participants discussed the considerations for treating a patient diagnosed with stage IIB lung adenocarcinoma.

During a Targeted Oncology™ Case-Based Roundtable™ event, Sarah M. Larson, MD, discussed the approach to treating a patient with transplant-eligible newly diagnosed multiple myeloma.

During a Targeted Oncology™ Case-Based Roundtable™ event, Stephen A. Schuster, MD, discussed the 5-year outcomes of the L-MIND trial of tafasitamab and lenalidomide for patients with relapsed/refractory diffuse large B-cell lymphoma.

During a Targeted Oncology™ Case-Based Roundtable™ event, Hans Hammers, MD, PhD, and participants discussed their experiences using lenvatinib to treat patients with advanced clear cell renal cell carcinoma.

During a Targeted Oncology™ Clinical Case Forum™ event, Terry P. Mamounas, MD, MPH, discussed the treatment landscape for patients with HER2-positive breast cancer.

During a Targeted Oncology™ Case-Based Roundtable™ event, Tanya B. Dorff, and participants, discussed the case of a patient with metastatic castration-resistant prostate cancer who has already received enzalutamide and docetaxel.

During a Targeted Oncology™ Case-Based Roundtable™ event, Michael B. Atkins, MD, and participants discussed the case of a 73-year-old man with a history of melanoma whose disease is now metastatic.

During a Targeted Oncology™ Case-Based Roundtable™ event, Ashwin Kishtagari, MD, discussed important findings on treating patients with high-risk myelofibrosis.

During a Targeted Oncology™ Case-Based Roundtable™ event, Joshua K. Sabari, MD, discussed with participants how they would use the FDA-approved therapies amivantamab and mobocertinib for patients with non–small cell lung cancer and an EGFR exon 20 insertion alteration. This is the second of 2 articles based on this event.

During a Targeted Oncology™ Case-Based Roundtable™ event, Raja Mudad, MD, discussed factors that influence the choice of immunotherapy or chemoimmunotherapy for a patient with metastatic non–small cell lung cancer.

During a Targeted Oncology™ Case-Based Roundtable™ event, Claudine Isaacs, MD, discussed with participants what they see as the role of elacestrant for patients with ER+, HER2-negative breast cancer. This is the second of 2 articles based on this event.

During a Targeted Oncology™ Case-Based Roundtable™ event, Shaji Kumar, MD, discussed with participants the key considerations of administering the bispecific T-cell engager teclistamab for patients with relapsed/refractory multiple myeloma.

In a live virtual event, Jens Hillengass discussed the results of the MajesTEC-1 study and how teclistamab is used to treat patients with relapsed/refractory multiple myeloma. This is the second article in a 2-article series on this case.

During a Targeted Oncology™ Case-Based Roundtable™ event, Benjamin Garmezy, MD, reviewed updated results of trial of frontline combination therapies for patients with advanced renal cell carcinoma.

During a Targeted Oncology™ Case-Based Roundtable™ event, Michael B. Atkins, MD, discussed data from the RELATIVITY-047 trial of nivolumab plus relatlimab for patients with metastatic melanoma. This is the second of 2 articles based on this event.

During a Targeted Oncology™ Case-Based Roundtable™ event, Randy F. Sweis, MD, discussed with participants their experiences using tivozanib and lenvatinib/everolimus in patients who have received at least 2 prior lines of therapy for advanced renal cell carcinoma. This is the second of 2 articles based on this event.

During a Targeted Oncology™ Case-Based Roundtable™ event, Deepak Kilari, MD, discussed with participants what real-world patient conditions would impact their choice of frontline therapy for metastatic renal cell carcinoma. This is the second of 2 articles based on this event.

During a Targeted Oncology™ Case-Based Roundtable™ event, Joshua K. Sabari, MD, discussed research supporting the use of amivantamab for patients with non–small cell lung cancer and an EGFR exon 20 insertion, including data comparing with real-world cohorts of similar patients treated with other agents.

During a Targeted Oncology™ Case-Based Roundtable™ event, Claudine Isaacs, MD, discussed with participants their reactions to the data from the phase 3 EMERALD study of elacestrant for patients with metastatic ER+ breast cancer.

During a Targeted Oncology™ Case-Based Roundtable™ event, Cyrus Khan, MD, discussed the case of a patient with relapsed/refractory diffuse large B-cell lymphoma who was referred for chimeric antigen receptor T-cell therapy and was place on a waiting list for treatment.

During a Targeted Oncology™ Case-Based Roundtable™ event, Paul D. DiSilvestro, MD, discussed the key trials supporting the use of PARP inhibitor maintenance therapy for patients with advanced ovarian cancer.

During a live virtual event, Sarah Yenser Wood, RN, MSN, ANP, AOCNP, and a panel of oncology nurses discussed their approaches to management of patients receiving first-line regimens for advanced or metastatic renal cell carcinoma.

During a Targeted Oncology™ Case-Based Roundtable™ event, Rafael Fonseca, MD, discussed the treatment paradigm for relapsed/refractory multiple myeloma and how the BCMA target now plays a role.

In a live virtual event, Jens Hillengass discussed the available treatment strategies for patients with relapsed/refractory multiple myeloma. This is first of 2 articles based on this event.

During a Targeted Oncology™ Case-Based Roundtable™ event, Richard Kim, MD, discussed regimens for biliary tract cancers including the results of the TOPAZ-1 trial of additional durvalumab.

During a Targeted Oncology™ Case-Based Roundtable™ event, Michael B. Atkins, MD, discussed with other oncologists what efficacy and safety data aid them in choosing an immunotherapy regimen for patients with metastatic melanoma. This is the first of 2 articles based on this event.

During a Targeted Oncology™ Case-Based Roundtable™ event, Randy F. Sweis, MD, discussed possible therapy options for a patient with metastatic renal cell carcinoma whose disease progressed on frontline therapy.